DefenCath Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adults

The clinical adjudication committee (CAC) confirmed and assessed cases of CRBSI.3 The CAC-adjudicated CRBSI rate was 2.3% in the DefenCath group vs 8% in the heparin group, with event rates of 0.13 and 0.46 per 1000 catheter days, respectively, indicating a significant delay in time to CRBSI (P< .001). There were no significant differences in time to catheter removal or catheter patency loss between the study groups, and mortality rates were comparable at 5%.2 Safety Investigators for the LOCK IT-100 trial assessed safety in 797 adult patients. Remaining solution must be discarded, as vials are for single-patiënt, single-use only.1 ¦ CONFERENCE COVERAGE Maui Derm 2024 Every month, Drug Topics'sister brands across MJH Life Sciences cover dozens of medical conferences, reporting on the latest news, education, and updates that impact the delivery of health care.